Insurers put in bid for biosimilar naming

Share this article:

Brand-name marketers may support unique names for biosimilar products, but the Wall Street Journal reports an array of pharmacies, health insurers and unions are urging the FDA to require biosimilars share the same name as the drugs they imitate, just like generics and branded drugs do.

The no-unique-name coalition says having multiple names for biosimilars that refer to the same branded drug will confuse doctors and patients. They also say multiple names for similarly indicated drugs could increase the risk of prescription errors.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.